CervoMed reports Q2 2024 net loss $2.3M, cash $50.9M; DLB trial enrolled, topline Dec 2024

CervoMed Inc.

Net loss $2.3M in Q2 2024 vs $1.4M in Q2 2023; operating loss $3.0M vs $1.2M.
Cash, equivalents and marketable securities $50.9M at June 30, 2024, up from $7.8M at Dec 31, 2023.
Completed enrollment in Phase 2b RewinD-LB trial (neflamapimod for early-stage DLB) in June 2024; topline data expected Dec 2024.
Private placement in April 2024 raised $50M upfront, with potential total proceeds up to $149.4M.
NIA grant revenue $5.6M for H1 2024 vs $3.1M for H1 2023; cash runway extended through 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.